Tirzepatide (GLP-1/GIP) Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research
[50,51] Potential biologics have been generated to target pro-inflammatory cytokines, such as IL-1, interferon (IFN)-, IFN-, IL-6, TNF-, IL-17, and IL-21, and several clinical trials that aim at inhibiting the activities of these mediators have been initiated
Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al
The inclusion of benzyl alcohol serves as a bacteriostatic preservative, which inhibits the growth of potentially contaminating bacteria
It belongs to a class of drugs known as multi-receptor agonists, and its mechanism of action is notably broad: it simultaneously activates three hormone receptors the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor